RecruitingHereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Eligible age
18+ yrs
Accepts
All genders
Locations
11 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Sponsor: ADARx Pharmaceuticals, Inc.
You may qualify if…
- ✓ Have a documented diagnosis of HAE (Type I or II)
- ✓ Completed Study ADX-324-301
- ✓ Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)
You may not qualify if…
- ✕ A negative reaction to study drug in ADX-324-301
Where it's recruiting
Source: ClinicalTrials.gov · NCT07428499 · last updated 2026-06-16